Slower-than-expected uptake of its Provenge prostate cancer drug forced Seattle biotech company Dendreon to announce 500 job cuts this afternoon,… Read More
During its second quarter financial statement last week, Bellevue’s Motricity hinted at upcoming changes and cost-cutting measures in response to… Read More
